Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Barriers to Brain Stimulation Therapies for Treatment-Resistant Depression: Beyond Cost Effectiveness.

Goldbloom DS, Gratzer D.

Can J Psychiatry. 2019 Dec 9:706743719893584. doi: 10.1177/0706743719893584. [Epub ahead of print] No abstract available.

PMID:
31818129
2.

Magnetic seizure therapy (MST) for major depressive disorder.

Daskalakis ZJ, Dimitrova J, McClintock SM, Sun Y, Voineskos D, Rajji TK, Goldbloom DS, Wong AHC, Knyahnytska Y, Mulsant BH, Downar J, Fitzgerald PB, Blumberger DM.

Neuropsychopharmacology. 2020 Jan;45(2):276-282. doi: 10.1038/s41386-019-0515-4. Epub 2019 Sep 5.

PMID:
31486777
3.

Invited commentary: ACCESS Open Minds/Esprits ouverts-A seismic shift in Canadian mental healthcare.

Goldbloom DS.

Early Interv Psychiatry. 2019 Jun;13 Suppl 1:12-13. doi: 10.1111/eip.12812. No abstract available.

PMID:
31243914
4.

Electroconvulsive therapy for depression with comorbid borderline personality disorder or post-traumatic stress disorder: A matched retrospective cohort study.

Kaster TS, Goldbloom DS, Daskalakis ZJ, Mulsant BH, Blumberger DM.

Brain Stimul. 2018 Jan - Feb;11(1):204-212. doi: 10.1016/j.brs.2017.10.009. Epub 2017 Oct 19.

PMID:
29111076
5.

The Mental Health Commission of Canada is three years old: an update and reflection.

Goldbloom DS.

Can J Nurs Res. 2010 Sep;42(3):101-4. No abstract available.

PMID:
21086779
6.

On quantifying quality.

Lin E, Durbin J, Goldbloom DS.

Can J Psychiatry. 2010 Sep;55(9):537-8. No abstract available.

PMID:
20840800
7.

From the age of enlightenment to the age of effectiveness: clinical trials in psychiatry.

Goldbloom DS.

Can J Psychiatry. 2010 Mar;55(3):115-6. No abstract available.

PMID:
20370960
8.

Unacceptable status quo in access to mental health care.

Goldbloom DS.

CMAJ. 2010 Jan 12;182(1):112. doi: 10.1503/cmaj.092029. No abstract available. Erratum in: CMAJ. 2010 Mar 23;182(5):482.

9.

Prevalence of psychiatric disorders among Toronto hospital workers one to two years after the SARS outbreak.

Lancee WJ, Maunder RG, Goldbloom DS; Coauthors for the Impact of SARS Study.

Psychiatr Serv. 2008 Jan;59(1):91-5. doi: 10.1176/ps.2008.59.1.91.

10.

Community treatment orders in Toronto: the emerging data.

Hunt AM, da Silva A, Lurie S, Goldbloom DS.

Can J Psychiatry. 2007 Oct;52(10):647-56.

PMID:
18020112
11.

Mental illness and cardiovascular mortality: searching for the links.

Goldbloom DS, Kurdyak P.

CMAJ. 2007 Mar 13;176(6):787-8. No abstract available.

12.

Long-term psychological and occupational effects of providing hospital healthcare during SARS outbreak.

Maunder RG, Lancee WJ, Balderson KE, Bennett JP, Borgundvaag B, Evans S, Fernandes CM, Goldbloom DS, Gupta M, Hunter JJ, McGillis Hall L, Nagle LM, Pain C, Peczeniuk SS, Raymond G, Read N, Rourke SB, Steinberg RJ, Stewart TE, VanDeVelde-Coke S, Veldhorst GG, Wasylenki DA.

Emerg Infect Dis. 2006 Dec;12(12):1924-32.

13.

Beliefs and expectations regarding etiology, treatment and outcome in bulimia nervosa.

McFarlane TL, Olmsted MP, Goldbloom DS.

Eat Weight Disord. 2005 Sep;10(3):187-92.

PMID:
16277141
14.

Meeting mania 2004.

Goldbloom DS.

BMJ. 2004 Dec 18;329(7480):1467-9. No abstract available.

15.

Tunnelling to 50: an exploratory medical memoir.

Goldbloom DS.

CMAJ. 2004 Dec 7;171(12):1473-4. No abstract available.

16.

Commentary: refinement required before implementation.

Goldbloom DS.

Hosp Q. 2000-2001 Winter;4(2):51-2. No abstract available.

PMID:
11484624
17.

Significant developments in psychiatry: implications for community mental health.

Garfinkel PE, Goldbloom DS.

Can J Commun Ment Health. 2000 Fall;19(2):161-5. No abstract available.

PMID:
11381735
18.

Comparisons of men with full or partial eating disorders, men without eating disorders, and women with eating disorders in the community.

Woodside DB, Garfinkel PE, Lin E, Goering P, Kaplan AS, Goldbloom DS, Kennedy SH.

Am J Psychiatry. 2001 Apr;158(4):570-4.

PMID:
11282690
19.

Mental health--getting beyond stigma and categories.

Garfinkel PE, Goldbloom DS.

Bull World Health Organ. 2000;78(4):503-5. No abstract available.

20.

A randomized controlled trial of fluoxetine and cognitive behavioral therapy for bulimia nervosa: short-term outcome.

Goldbloom DS, Olmsted M, Davis R, Clewes J, Heinmaa M, Rockert W, Shaw B.

Behav Res Ther. 1997 Sep;35(9):803-11.

PMID:
9299800
21.

The early Canadian history of anorexia nervosa.

Goldbloom DS.

Can J Psychiatry. 1997 Mar;42(2):163-7.

PMID:
9067065
22.

Rediscovering general psychiatry: creation of an academic division.

Goldbloom DS, Buckingham RA, Voore P.

Can J Psychiatry. 1997 Feb;42(1):58-62.

PMID:
9040925
23.

Pharmacotherapy of Bulimia Nervosa.

Goldbloom DS.

Medscape Womens Health. 1997 Jan;2(1):4.

PMID:
9746670
24.

Cerebral gray matter and white matter volume deficits in adolescent girls with anorexia nervosa.

Katzman DK, Lambe EK, Mikulis DJ, Ridgley JN, Goldbloom DS, Zipursky RB.

J Pediatr. 1996 Dec;129(6):794-803.

PMID:
8969719
25.

Purging and nonpurging forms of bulimia nervosa in a community sample.

Garfinkel PE, Lin E, Goering P, Spegg C, Goldbloom DS, Kennedy S, Kaplan AS, Woodside DB.

Int J Eat Disord. 1996 Nov;20(3):231-8.

PMID:
8912035
26.

Psychiatric practice for the coming decade.

Goldbloom DS, Garfinkel PE.

Can J Psychiatry. 1996 Apr;41(3):156-60.

PMID:
8722644
27.

The hormonal response to intravenous 5-hydroxytryptophan in bulimia nervosa.

Goldbloom DS, Garfinkel PE, Katz R, Brown GM.

J Psychosom Res. 1996 Mar;40(3):289-97.

PMID:
8861125
28.

Bulimia nervosa in a Canadian community sample: prevalence and comparison of subgroups.

Garfinkel PE, Lin E, Goering P, Spegg C, Goldbloom DS, Kennedy S, Kaplan AS, Woodside DB.

Am J Psychiatry. 1995 Jul;152(7):1052-8.

PMID:
7793442
29.

Oral imipramine and acute angle-closure glaucoma.

Epstein NE, Goldbloom DS.

Arch Ophthalmol. 1995 Jun;113(6):698; author reply 699. No abstract available.

PMID:
7786199
30.
31.

Valproate/nortriptyline interaction.

Fu C, Katzman M, Goldbloom DS.

J Clin Psychopharmacol. 1994 Jun;14(3):205-6. No abstract available.

PMID:
8027418
32.

Advances in the Treatment of Anorexia Nervosa and Bulimia Nervosa.

Kennedy SH, Goldbloom DS.

CNS Drugs. 1994 Mar;1(3):201-12. doi: 10.2165/00023210-199401030-00005.

PMID:
27520519
33.

Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine.

Kennedy SH, Goldbloom DS, Ralevski E, Davis C, D'Souza JD, Lofchy J.

J Clin Psychopharmacol. 1993 Dec;13(6):415-22.

PMID:
8120155
34.

The effect of the MAO-A selective inhibitor brofaromine on the plasma and urine concentrations of some biogenic amines and their acidic metabolites in bulimia nervosa.

Davis BA, Kennedy SH, Durden DA, D'Souza J, Goldbloom DS, Boulton AA.

Prog Neuropsychopharmacol Biol Psychiatry. 1993 Sep;17(5):747-63.

PMID:
7504824
35.

Alcohol misuse and eating disorders: aspects of an association.

Goldbloom DS.

Alcohol Alcohol. 1993 Jul;28(4):375-81. Review.

PMID:
8397519
36.
37.

Bulimia nervosa : a review of therapy research.

Garfinkel PE, Goldbloom DS.

J Psychother Pract Res. 1993 Winter;2(1):38-50.

38.

Eating disorders and alcohol abuse in women.

Goldbloom DS, Naranjo CA, Bremner KE, Hicks LK.

Br J Addict. 1992 Jun;87(6):913-9.

PMID:
1525533
39.

Advertising meal replacement products.

Goldbloom DS, Davis R, Kaplan AS, Kennedy SH, Rice C.

CMAJ. 1991 Aug 1;145(3):199-200. No abstract available.

40.

Adverse interaction of fluoxetine and cyproheptadine in two patients with bulimia nervosa.

Goldbloom DS, Kennedy SH.

J Clin Psychiatry. 1991 Jun;52(6):261-2.

PMID:
2055898
41.

Post-residency fellowship training.

Goldbloom DS, Kennedy SH.

Can J Psychiatry. 1991 Mar;36(2):151-2. No abstract available.

PMID:
2044035
42.

Electroconvulsive therapy training in Canada: a survey of senior residents in psychiatry.

Goldbloom DS, Kussin DJ.

Can J Psychiatry. 1991 Mar;36(2):126-8.

PMID:
2044032
43.

Current perspectives on drug therapies for anorexia nervosa and bulimia nervosa.

Kennedy SH, Goldbloom DS.

Drugs. 1991 Mar;41(3):367-77. Review.

PMID:
1711444
44.

Biochemical aspects of bulimia nervosa.

Goldbloom DS, Garfinkel PE, Shaw BF.

J Psychosom Res. 1991;35 Suppl 1:11-22. Review. No abstract available.

PMID:
1674288
45.

The serotonin hypothesis of bulimia nervosa: theory and evidence.

Goldbloom DS, Garfinkel PE.

Can J Psychiatry. 1990 Dec;35(9):741-4. Review.

PMID:
2282627
46.

Platelet serotonin uptake in bulimia nervosa.

Goldbloom DS, Hicks LK, Garfinkel PE.

Biol Psychiatry. 1990 Oct 1;28(7):644-7. No abstract available.

PMID:
2223931
47.

Infertility and eating disorders.

Stewart DE, Robinson E, Goldbloom DS, Wright C.

Am J Obstet Gynecol. 1990 Oct;163(4 Pt 1):1196-9.

PMID:
2220927
48.

Fluoxetine and neuroleptic malignant syndrome.

Halman M, Goldbloom DS.

Biol Psychiatry. 1990 Sep 15;28(6):518-21.

PMID:
2223920
49.

The clinician-investigator interface in psychiatry: II--The role of the Clinical Investigation Unit.

Garfinkel PE, Kennedy SH, Kaplan AS, Goldbloom DS.

Can J Psychiatry. 1989 Jun;34(5):364-8.

PMID:
2766188
50.

The clinician-investigator interface in psychiatry I--Values and problems.

Garfinkel PE, Goldbloom DS, Kaplan AS, Kennedy SH.

Can J Psychiatry. 1989 Jun;34(5):361-3. Review.

PMID:
2670172

Supplemental Content

Loading ...
Support Center